Biologics... Changing Treatment, Saving Lives

Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.

Events

In-Person & Online Events

Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.

Antibody Engineering with Novel Technologies Online Symposium

20 Nov 2024 | GMT (UTC+0)

NextGen Biomed 2025

12 - 14 Mar 2025 | London, UK

Cell 2025

11-12 Nov 2025 | London, UK

Online Activities

Our Monthly Science Exchanges and Webinars keep you connected to the conversation.

01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing

14/11/24 - Leading Innovations in Fab, ScFv, & VHH Production and Engineering

19/11/24 - Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy

All Online Activities
Community

About

NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.

More Info

Community

NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.

More Info

Media Partners

We work with leading journal publications on reciprocal marketing arrangements.

More Info
Services

In-Person Services

At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.

More Info

Digital Marketing Services

Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.

More Info
Resources

Browse All Resources

The latest in from nextgen biomed research & development

All NextGen Biomed Resources

Latest Resources

University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus

08/11/24 - The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK.

07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants

31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine

Featured Resource

Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes

On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Contact
Our Brands

Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.

Oxford Global

Precision Medicine

Discovery & Development

NextGen Biomed

Open document in a new tab

In-Person & Online Events

Online Activities

01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing

14/11/24 - Leading Innovations in Fab, ScFv, & VHH Production and Engineering

19/11/24 - Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy

About

Community

Media Partners

In-Person Services

Digital Marketing Services

Browse All Resources

Latest Resources

University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus

Featured Resource

Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes

Biologics... Changing Treatment, Saving Lives

Related Resources

Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges

Archon Biosciences Announces $20m of Seed Funding for its Nobel-Winning, AI-Driven Antibody Cage Technology

Conjugate, clean-up, & characterize ADCs on Unagi & Stunner

Subscribe to our newsletter